Login to Your Account



Other News To Note


Monday, February 13, 2012
• NeurogesX Inc., of San Mateo, Calif., said the FDA's Anesthetic and Analgesic Drug Products Advisory Committee did not recommend approval of Qutenza (capsaicin 8 percent patch) for management of neuropathic pain related to HIV-associated peripheral neuropathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription